DUSP22 and metabolic syndrome: To confirm that DUSP22 expression changes were associated with dyslipidemia and inflammation under metabolic stresses, we next constructed a special in vitro model using human hepatocyte L02 cells co-treated with conditional medium (CM) containing serum collected from NASH subjects (NASH Serum) or non-steatosis subjects (Non-steatosis Serum).